Quick Answer
Lakefront Biotherapeutics NV reported Total Assets of $3.41 billion for fiscal year 2025.
Lakefront Biotherapeutics NV — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Assets | $3.41B -17.6% |
$4.14B -5.1% |
$4.36B -8.0% |
$4.73B -8.8% |
$5.19B -9.2% |
$5.72B -5.8% |
| R&D Expense | $459.42M +37.0% |
$335.46M +39.0% |
$241.29M -10.6% |
$269.80M -15.8% |
$320.50M -38.8% |
$523.67M +24.7% |
- Lakefront Biotherapeutics NV reported Total Assets of $3.41 billion for fiscal year 2025.
- Lakefront Biotherapeutics NV showed a decrease of -17.6% in Total Assets compared to the prior fiscal year.
- Lakefront Biotherapeutics NV reported R&D Expense of $459.42 million for fiscal year 2025.
- Lakefront Biotherapeutics NV showed an increase of +37.0% in R&D Expense compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: